We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
PBH builds brands through advertising, innovation and broad distribution across consumer health categories.
PBH's Breathe Right and LaCorium to contribute $190 million in fiscal 2027 revenues, boosting sales.
PBH's e-commerce consumption grew at a double-digit rate, while competition and currency shifts pose risks.
Prestige Consumer Healthcare (PBH - Free Report) continues to build its consumer health brands through advertising, innovation and broad distribution, with growth across established franchises and Women’s Health. Acquisitions of Breathe Right and LaCorium are expected to expand the company’s revenue base in fiscal 2027. E-commerce growth reflects continued consumer demand for value, broad product selection and price transparency. However, intense competition, pricing pressure and foreign exchange fluctuations remain key challenges for Prestige Consumer.
Over the past year, this Zacks Rank #3 (Hold) stock has declined 20.5% compared with the 26.8% fall of the industry and the S&P 500 composite’s 18% growth.
The renowned consumer healthcare product company has a market capitalization of $2.30 billion. Its earnings yield of 9.4% is well ahead of the industry’s 2.7%. PBH surpassed earnings estimates in two of the trailing four quarters and missed on the other two occasions, delivering an average surprise of 1.8%.
Let’s delve deeper.
Upsides for PBH Stock
Focus on Brand-Building: Building consumer health brands remains central to Prestige Consumer’s long-term strategy, supported by targeted advertising, innovation and broad distribution across mass and e-commerce channels. First-quarter fiscal 2027 results continued to show traction across several established franchises. Dramamine and Fleet delivered ongoing consumption gains in Gastrointestinal, while Compound W led Dermatological growth. TheraTears and Debrox also grew, helping offset constrained Clear Eyes sales.
Management continues to develop Women’s Health through product innovation. Monistat maintained stable to growing market share despite continued category declines, while Summer’s Eve Ultimate Odor Protection remained a strong performer, with additional launches planned over the next several years. The company is applying the same model to Breathe Right.
Image Source: Zacks Investment Research
Acquisitions Aid Growth: Prestige Consumer has expanded its portfolio through acquisitions, including TheraTears, Hydralyte and Pillar5. In fiscal 2027, the company added two larger consumer-health platforms: the Breathe Right portfolio, which was closed on June 12, 2026, and LaCorium Health, closed on July 1, 2026. Breathe Right is expected to contribute approximately $200 million to annual revenues, while LaCorium is anticipated to contribute roughly $40 million, together increasing Prestige’s revenue base by nearly 20%. For fiscal 2027, the acquisitions are expected to account for approximately $190 million of revenues, lifting reported revenue guidance to $1,290-$1,315 million, while organic growth guidance remains 1% to 3%.
Breathe Right was largely integrated within 60 days of closing, with consumer awareness exceeding 90%, distribution across more than 20 countries and additional product extensions, including Menthol and Sport. LaCorium adds Dermal Therapy and other therapeutic skin care brands in Australia, with management targeting distributor optimization, sales integration and operating efficiencies over time.
E-Commerce Strength: Prestige Consumer continues to benefit from its long-term investment in digital channels and channel-agnostic distribution. E-commerce represented about 18% of net sales in fiscal 2026, up from low single digits in fiscal 2019. In the first quarter of fiscal 2027, e-commerce consumption again grew at a double-digit rate as consumers continued to seek value, broad assortment and price transparency online. Reported shipments were affected by retailer order timing, with roughly two percentage points of first-quarter growth pulled forward from the second quarter, but management still expects organic revenue growth for the first half.
What Concerns PBH Stock?
Intense Competition: The markets in which Prestige Consumer operates are highly competitive and include numerous national and global manufacturers, distributors, marketers and retailers. The company faces competition on brand recognition, product performance, value, price and product availability. Management also highlighted heightened quality scrutiny across sterile eye care following recent category headlines, increasing the importance of consistent supply and execution. Competitive innovation and lower-priced alternatives can constrain share gains and limit pricing flexibility, particularly during periods of sustained consumer caution.
Currency Fluctuations: Prestige Consumer relies on brokers and distributors for the sale of its products in foreign countries, with International OTC Healthcare representing about 16% of fiscal 2026 revenues. As a result, foreign exchange movements can create variability in reported results and influence pricing dynamics for products sourced from foreign third-party manufacturers.
PBH Stock Estimate Trend
In the past 60 days, the Zacks Consensus Estimate for PBH’s fiscal 2027 earnings per share (EPS) has increased 0.3% to $4.56.
The Zacks Consensus Estimate for the company’s fiscal 2027 revenues is pegged at $1.29 billion. This suggests a jump of 18.9% from the year-ago reported number.
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7%. Shares of the company have dropped 3.1% compared with the industry’s 26.8% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 20.4% compared with the industry’s 26.7% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 30.8% compared with the industry’s 7.1% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
Key Takeaways
Prestige Consumer Healthcare (PBH - Free Report) continues to build its consumer health brands through advertising, innovation and broad distribution, with growth across established franchises and Women’s Health. Acquisitions of Breathe Right and LaCorium are expected to expand the company’s revenue base in fiscal 2027. E-commerce growth reflects continued consumer demand for value, broad product selection and price transparency. However, intense competition, pricing pressure and foreign exchange fluctuations remain key challenges for Prestige Consumer.
Over the past year, this Zacks Rank #3 (Hold) stock has declined 20.5% compared with the 26.8% fall of the industry and the S&P 500 composite’s 18% growth.
The renowned consumer healthcare product company has a market capitalization of $2.30 billion. Its earnings yield of 9.4% is well ahead of the industry’s 2.7%. PBH surpassed earnings estimates in two of the trailing four quarters and missed on the other two occasions, delivering an average surprise of 1.8%.
Let’s delve deeper.
Upsides for PBH Stock
Focus on Brand-Building: Building consumer health brands remains central to Prestige Consumer’s long-term strategy, supported by targeted advertising, innovation and broad distribution across mass and e-commerce channels. First-quarter fiscal 2027 results continued to show traction across several established franchises. Dramamine and Fleet delivered ongoing consumption gains in Gastrointestinal, while Compound W led Dermatological growth. TheraTears and Debrox also grew, helping offset constrained Clear Eyes sales.
Management continues to develop Women’s Health through product innovation. Monistat maintained stable to growing market share despite continued category declines, while Summer’s Eve Ultimate Odor Protection remained a strong performer, with additional launches planned over the next several years. The company is applying the same model to Breathe Right.
Image Source: Zacks Investment Research
Acquisitions Aid Growth: Prestige Consumer has expanded its portfolio through acquisitions, including TheraTears, Hydralyte and Pillar5. In fiscal 2027, the company added two larger consumer-health platforms: the Breathe Right portfolio, which was closed on June 12, 2026, and LaCorium Health, closed on July 1, 2026. Breathe Right is expected to contribute approximately $200 million to annual revenues, while LaCorium is anticipated to contribute roughly $40 million, together increasing Prestige’s revenue base by nearly 20%. For fiscal 2027, the acquisitions are expected to account for approximately $190 million of revenues, lifting reported revenue guidance to $1,290-$1,315 million, while organic growth guidance remains 1% to 3%.
Breathe Right was largely integrated within 60 days of closing, with consumer awareness exceeding 90%, distribution across more than 20 countries and additional product extensions, including Menthol and Sport. LaCorium adds Dermal Therapy and other therapeutic skin care brands in Australia, with management targeting distributor optimization, sales integration and operating efficiencies over time.
E-Commerce Strength: Prestige Consumer continues to benefit from its long-term investment in digital channels and channel-agnostic distribution. E-commerce represented about 18% of net sales in fiscal 2026, up from low single digits in fiscal 2019. In the first quarter of fiscal 2027, e-commerce consumption again grew at a double-digit rate as consumers continued to seek value, broad assortment and price transparency online. Reported shipments were affected by retailer order timing, with roughly two percentage points of first-quarter growth pulled forward from the second quarter, but management still expects organic revenue growth for the first half.
What Concerns PBH Stock?
Intense Competition: The markets in which Prestige Consumer operates are highly competitive and include numerous national and global manufacturers, distributors, marketers and retailers. The company faces competition on brand recognition, product performance, value, price and product availability. Management also highlighted heightened quality scrutiny across sterile eye care following recent category headlines, increasing the importance of consistent supply and execution. Competitive innovation and lower-priced alternatives can constrain share gains and limit pricing flexibility, particularly during periods of sustained consumer caution.
Currency Fluctuations: Prestige Consumer relies on brokers and distributors for the sale of its products in foreign countries, with International OTC Healthcare representing about 16% of fiscal 2026 revenues. As a result, foreign exchange movements can create variability in reported results and influence pricing dynamics for products sourced from foreign third-party manufacturers.
PBH Stock Estimate Trend
In the past 60 days, the Zacks Consensus Estimate for PBH’s fiscal 2027 earnings per share (EPS) has increased 0.3% to $4.56.
The Zacks Consensus Estimate for the company’s fiscal 2027 revenues is pegged at $1.29 billion. This suggests a jump of 18.9% from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7%. Shares of the company have dropped 3.1% compared with the industry’s 26.8% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 20.4% compared with the industry’s 26.7% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 30.8% compared with the industry’s 7.1% growth over the past year.